MND: Amarin corporation has publish results of a Phase III clinical trial of their AMR101 drug which is an ethyl icosapentate (ethyl-EPA).
- “..The MARINE study, investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL)”
- Reported results are significant ”….patient group treated with 4 grams of AMR101 showed a significant median TG decrease of 33 % (P < 0.0001) compared to placebo, and the patient group treated with 2 grams of AMR101 showed a significant median TG decrease of 20 % (P = 0.0051) compared to placebo…”
MND: so what is AMR101 and how does is differ from your over the counter fish oil supplement
-
Wiki’s page on Ethyl eicosapentaenoic acid defines it as : “….Ethyl eicosapentaenoic acid (E-EPA) is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA)…”
-
It is has possible application on:
-
Cardiovascular Disease
-
Diabetes
-
Mental Health
-
MND: For background on Omega’s, we are going to link you to the Linus Pauling/U. of Oregon site. But what makes this synthetic so much more potent?
MND:Another aspect of this E-EPA potential is about Huntington’s Disease as discuused on the HDLighthouse site .
Still not clear what makes E-EPA proprietary and “pharmaceutical” , except perhaps the route of clinical trials?
We have left the “Nutrition” field….
hello!,I love your writing very so much! proportion we keep in touch more about your article on AOL? I need a specialist on this space to resolve my problem. Maybe that’s you! Taking a look forward to peer you.
Wonderful publish, very informative. I ponder why the other specialists of this sector do not notice this. You should proceed your writing. I am confident, you’ve a huge readers’ base already!|What’s Happening i am new to this, I stumbled upon this I’ve discovered It positively useful and it has helped me out loads. I am hoping to give a contribution & assist different customers like its helped me. Great job.